Avenue Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ATXI Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
30 Sep 24	BuyUS$1,250	Jay Kranzler	Individual		500	US$2.50
11 Dec 23	SellUS$86,560	Robert Davidow	Individual		8,226.65	US$11.25

Insider Buying: ATXI insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1255.4%.

Top 17 shareholders own 13.11% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
5.24%	Armistice Capital LLC	75,000	US$155.6k	0%	no data
3.3%	Fortress Biotech, Inc.	47,299	US$98.1k	13.2%	no data
2.61%	Sabby Management, LLC	37,394	US$77.6k	318%	1.02%
1.2%	Robert Davidow	17,206	US$35.7k	-1.48%	no data
0.33%	Lindsay Rosenwald	4,671	US$9.7k	0%	no data
0.22%	Tower Research Capital Europe Limited	3,205	US$6.7k	2,620%	no data
0.049%	Geode Capital Management, LLC	695	US$1.4k	0%	no data
0.047%	UBS Asset Management AG	673	US$1.4k	0%	no data
0.043%	Jay Kranzler	620	US$1.3k	417%	no data
0.043%	The Vanguard Group, Inc.	617	US$1.3k	0%	no data
0.0084%	Neil Herskowitz	120	US$248.9	0.84%	no data
0.0043%	Wells Fargo & Company, Securities and Brokerage Investments	61	US$126.5	1.67%	no data
0.0031%	Curtis Oltmans	44	US$91.2	0%	no data
0.00056%	Royal Bank of Canada, Banking & Securities Investments	8	US$16.6	14.3%	no data
0.00056%	EMFO, LLC	8	US$16.6	14.3%	no data
0.00049%	Bank of America Corporation, Asset Management Arm	7	US$14.6	0%	no data
0.00007%	JPMorgan Chase & Co, Brokerage and Securities Investments	1	US$2.1	0%	no data